Alfuzosin
Alfuzosin, Uroxatral (alfuzosin) is a small molecule pharmaceutical. Alfuzosin was first approved as Uroxatral on 2003-06-12. It is used to treat prostatic hyperplasia in the USA. The pharmaceutical is active against alpha-1A adrenergic receptor, alpha-1B adrenergic receptor, and alpha-1D adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Uroxatral (generic drugs available since 2011-07-18)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alfuzosin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| UROXATRAL | Concordia Laboratories | N-021287 RX | 2003-06-12 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alfuzosin hydrochloride | ANDA | 2024-01-19 |
| uroxatral | New Drug Application | 2021-08-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| prostatic hyperplasia | EFO_0000284 | D011470 | N40 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
54 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | 1 | 7 | 8 | 8 | 24 |
| Prostatic diseases | D011469 | — | N42.9 | — | — | — | 1 | 1 | 2 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | — | — | 1 | 1 | — | 2 |
| Choroid diseases | D015862 | HP_0000610 | H31.9 | — | — | — | 1 | — | 1 |
| Renal colic | D056844 | EFO_1001412 | N23 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney calculi | D007669 | EFO_0004253 | N20 | — | — | 2 | — | 1 | 3 |
| Neurogenic urinary bladder | D001750 | HP_0000011 | N31 | — | — | 3 | — | — | 3 |
| Urinary retention | D016055 | HP_0000016 | R33 | — | — | 2 | — | 1 | 3 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | 1 | — | 1 | 2 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | 1 | — | 1 | 2 |
| Urinary calculi | D014545 | — | N20.9 | — | — | 1 | — | 1 | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 1 | — | — | 1 |
| Hydronephrosis | D006869 | EFO_0005562 | N13.30 | — | — | 1 | — | — | 1 |
| Ureteral calculi | D014514 | — | — | — | — | 1 | — | — | 1 |
| Colic | D003085 | HP_0011848 | R10.83 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Constipation | D003248 | HP_0002019 | K59.0 | — | 1 | — | — | — | 1 |
| Nephrolithiasis | D053040 | — | N20.0 | — | 1 | — | — | — | 1 |
| Urolithiasis | D052878 | — | N20-N23 | — | 1 | — | — | — | 1 |
| Ureterolithiasis | D053039 | EFO_1001228 | N20.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute disease | D000208 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Alfuzosin |
| INN | alfuzosin |
| Description | Alfuzosin is a monocarboxylic acid amide, a tetrahydrofuranol and a member of quinazolines. It has a role as an antineoplastic agent, an antihypertensive agent and an alpha-adrenergic antagonist. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC |
Identifiers
| PDB | — |
| CAS-ID | 81403-80-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL709 |
| ChEBI ID | 51141 |
| PubChem CID | 2092 |
| DrugBank | DB00346 |
| UNII ID | 90347YTW5F (ChemIDplus, GSRS) |
Target
Agency Approved
ADRA1A
ADRA1A
ADRA1B
ADRA1B
ADRA1D
ADRA1D
Organism
Homo sapiens
Gene name
ADRA1A
Gene synonyms
ADRA1C
NCBI Gene ID
Protein name
alpha-1A adrenergic receptor
Protein synonyms
Alpha-1A adrenoceptor, Alpha-1A adrenoreceptor, Alpha-1C adrenergic receptor, Alpha-adrenergic receptor 1c, G protein coupled receptor
Uniprot ID
Mouse ortholog
Adra1a (11549)
alpha-1A adrenergic receptor (Q8BV77)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Alfuzosin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,562 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,125 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use